Responses
Clinical/translational cancer immunotherapy
Original research
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation
Compose a Response to This Article
Other responses
No responses have been published for this article.
